Healthcare Industry News: neuromodulation
News Release - September 12, 2013
Cyberonics Names Rohan J. Hoare, Ph.D. Senior Vice President, Strategic PlanningHOUSTON, Sept. 12, 2013 -- (Healthcare Sales & Marketing Network) -- Cyberonics, Inc. (CYBX) today announced that Rohan J. Hoare, Ph.D., has joined the company as Senior Vice President, Strategic Planning. Dr. Hoare will lead business strategy development and execution and functional capability building within Cyberonics.
Previously, Dr. Hoare was the President of St. Jude neuromodulation Division, which designs, manufactures and sells neuromodulation devices for the treatment of chronic pain, movement disorders and chronic migraine headache. In his nine years with St. Jude neuromodulation (formerly Advanced neuromodulation Systems, Inc.), he held leadership roles in strategy, therapy development and R&D, where he was responsible for developing and launching numerous products and therapies. He began his career with McKinsey & Co., a premiere strategy consulting firm, where he served clients in high tech, med tech and healthcare payor and providers for nearly a decade.
"We are pleased to welcome Rohan to the Cyberonics management team. Rohan has many years of experience in the medical device industry and specifically within neuromodulation," said Dan Moore, Cyberonics' President and Chief Executive Officer. "His experience will be invaluable as we continue to build the company and plan for successful and profitable growth over the long term."
Rohan received a Bachelor of Science in Physics and was awarded Faculty of Science Scholar honors at Monash University, Melbourne, Australia. He continued his studies at Harvard University as a Fulbright Scholar, where he received a Master of Arts and a Ph.D. in Physics.
About Cyberonics, Inc. and the VNS TherapyŽ System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning building the company and achieving profitable growth over the long term. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy and sales of our products; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of new products, including VNS Therapy for the treatment of other indications; satisfactory completion of the post-market registry required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new products and indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 26, 2013 and our Quarterly Report on Form 10-Q for the fiscal quarter ended July 26, 2013.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.